Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 14 Urinary Bladder Neoplasms 13 Colorectal Neoplasms 10 Carcinoma, Merkel Cell 9 Breast Neoplasms 9 Carcinoma, Renal Cell 7 Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Non-Small-Cell Lung 6 Small Cell Lung Carcinoma 4 Carcinoma, Hepatocellular 4 Turcot syndrome 3 Stomach Neoplasms 3 Neuroendocrine Tumors 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Penile Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Melanoma 2 Lung Neoplasms 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Neuroendocrine 2 Uterine Cervical Neoplasms 1

Interventions

Cyclophosphamide 241 Rituximab 223 Etoposide 138 Filgrastim 113 Vincristine 112 Doxorubicin 104 Prednisone 90 Cytarabine 90 Methotrexate 79 fludarabine phosphate 77 Radiotherapy 76 Peripheral Blood Stem Cell Transplantation 71 Melphalan 71 Busulfan 60 Tacrolimus 48 Dexamethasone 48 Mycophenolic Acid 46 Carmustine 46 Granulocyte Colony-Stimulating Factor 44 fludarabine 43 Antilymphocyte Serum 40 Ifosfamide 38 sargramostim 34 Whole-Body Irradiation 34 Cyclosporine 33 Bortezomib 32 Gemcitabine 30 Methylprednisolone 27 Bendamustine Hydrochloride 27 Lenalidomide 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma × avelumab × Clear all

NCT03046953 2024-07-16

AVAIL-T

University of Birmingham

Phase 2 Completed

35 enrolled 21 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡